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AbstrAct
Outcomes for patients diagnosed with the bone cancer osteosarcoma have not 
improved significantly in the last four decades. Only around 60% of patients and about 
a quarter of those with metastatic disease survive for more than five years. Although 
DNA-damaging chemotherapy drugs can be effective, they can provoke serious or 
fatal adverse effects including cardiotoxicity and therapy-related cancers. Better 
and safer treatments are therefore needed. We investigated the anti-osteosarcoma 
activity of IAP antagonists (also known as Smac mimetics) using cells from primary 
and metastatic osteosarcomas that arose spontaneously in mice engineered to lack 
p53 and Rb expression in osteoblast-derived cells. The IAP antagonists SM-164, GDC-
0152 and LCL161, which efficiently target XIAP and cIAPs, sensitized cells from most 
osteosarcomas to killing by low levels of TNFα but not TRAIL. RIPK1 expression levels 
and activity correlated with sensitivity. RIPK3 levels varied considerably between 
tumors and RIPK3 was not required for IAP antagonism to sensitize osteosarcoma 
cells to TNFα. IAP antagonists, including SM-164, lacked mutagenic activity. These data 
suggest that drugs targeting XIAP and cIAP1/2 may be effective for osteosarcoma 
patients whose tumors express abundant RIPK1 and contain high levels of TNFα, and 
would be unlikely to provoke therapy-induced cancers in osteosarcoma survivors.
IntroductIon
The primary bone cancer osteosarcoma typically 
arises in teenagers, with an incidence of 8 per million per 
year in adolescents and young adults. Osteosarcoma is 
rare in people aged 25-60, but its incidence increases in 
older individuals including those with Paget’s disease [1]. 
The introduction of high dose multi-agent chemotherapy 
in the 1970s, particularly doxorubicin and cisplatin, led 
to substantial increases in survival rates for osteosarcoma 
patients [2]. Unfortunately, little recent progress has 
been made. Around 40% of patients diagnosed with 
osteosarcoma, and almost three quarters of those with 
metastatic disease, still die within five years of diagnosis 
[2]. 
Almost 90% of the individuals who survive 
osteosarcoma suffer from disease and/or disability due to 
their treatment [3]. Most osteosarcoma patients are treated 
with high dose methotrexate, doxorubicin and cisplatin, 
before and after surgery [4]. These chemotherapeutic 
agents can cause severe and sometimes fatal adverse 
effects including cardiac and kidney damage, neurotoxicity 
and/or therapy-related second cancers [5], which preclude 
administration of higher, more effective, doses of these 
drugs. Around 1 in 13 osteosarcoma survivors develop 
subsequent malignancies within 30 years of diagnosis [6], 
more than half of whom die of their second cancers within 
five years [6]. To improve outcomes for osteosarcoma 
patients, drugs are needed that can either (1) eliminate 
osteosarcoma cells as sole agents, without causing severe 
sequelae, or (2) cooperate with lower doses of currently 
used chemotherapies to destroy tumor cells more safely.
A number of anti-cancer agents have been recently 
developed that directly engage programed cell death 
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pathways, rather than initially provoking DNA damage 
in order to secondarily stimulate tumor cell death. One 
class of new agents acts by antagonizing members of 
the IAP family of pro-survival proteins. One member 
of this family, XIAP, inhibits caspases-3, -7 and -9 to 
block apoptosis [7]. Two other relatives, cIAP1 and 
cIAP2, are ineffective caspase inhibitors [8]. Instead, 
these proteins participate in a complex assembled around 
the cytoplasmic domain of TNF-R1 that promotes 
canonical NF-κB-mediated expression of proteins with 
roles in pro-cancerous process including proliferation, 
invasion and inflammation [9-11]. cIAP1 and 2 were 
reported to be frequently overexpressed in osteosarcomas 
and their amplification-mediated upregulation drove 
osteosarcomagenesis in p53 heterozygous mice [12]. 
Crucially, cIAP1/2 can poly-ubiquitinate the kinase 
RIPK1, preventing it from transitioning into secondary 
complexes, the “ripoptosome” and “necrosome”, 
that initiate caspase-dependent apoptotic or caspase-
independent necroptotic cell death respectively [13].
IAP activity within cells can be reduced by Smac/
Diablo, a natural IAP antagonist protein [14, 15]. A 
number of “IAP antagonists” (also known as “Smac 
mimetics”) have been created that bind IAPs in a 
similar way to Smac, relieving XIAP-mediated caspase 
inhibition and promoting the proteosomal degradation 
of cIAP1 and 2 [16]. This loss of cIAP1/2 results in 
CYLD-mediated deubiquitination of RIPK1, leading to 
formation of the ripoptosome [17]. Caspase-8 is activated 
within this complex, and can then proteolytically activate 
caspases-3 and -7. If the IAP antagonist drug prevents 
XIAP from inhibiting these executioner caspases, they 
can induce apoptosis. RIPK1 can also promote caspase-
independent, necroptotic cell death [18, 19]. This pathway 
classically involves a relative of RIPK1, RIPK3, and the 
pseudokinase MLKL [20, 21]. Necroptosis is negatively 
regulated by caspase-8 [22] and can be provoked by TNFα 
treatment of cells lacking IAP and caspase activity. 
IAP antagonist drugs can be sub-classified by their 
structures and specificities. “Monovalent” IAP antagonists 
such as Debio1143(AT-406) [23], GDC-0152 [24] and 
LCL161 [25] resemble the amino terminus of processed 
Smac/Diablo and can interact with a single site within an 
IAP protein. Bivalent agents, including Birinapant [26], 
BV6 [27] and SM-164 [28], possess two such moieties. 
They tend to exhibit higher affinities and potencies 
than the monovalent drugs, at least in vitro, but their 
size necessitates intravenous administration [29]. IAP 
antagonists also vary in their reported specificities for 
XIAP versus cIAP1/2. Some, like DEBIO1143/AT406 and 
Birinapant [23, 26], preferentially target cIAP1 and cIAP2 
rather than XIAP. Others, including BV6, LCL161, GDC-
0152 and SM-164, have similar affinities for XIAP, cIAP1 
and cIAP2 [24, 27, 28, 30].
Early phase clinical trials have revealed that most 
patients tolerate IAP antagonists, although high doses of 
at least some can trigger cytokine release syndrome due 
to their promotion of autocrine TNFα production [31]. 
As single agents, IAP antagonists triggered complete or 
partial remissions in a minority of patients with ovarian 
cancer, colon cancer, melanoma or MALT lymphomas, 
and stabilized disease in additional patients [29]. More 
promising data has emerged from studies in which 
patients were given IAP antagonists with standard anti-
cancer therapies. Over a third of poor-risk acute myeloid 
leukemia patients administered Debio1143 (AT-406) 
with daunorubicin and cytarabine experienced complete 
remissions, although half of these subsequently relapsed 
[32]. 
Pre-clinical studies revealed that IAP antagonists 
could also augment the cytotoxicity of other targeted 
therapies such as chromatin remodeling agents [33-35]. 
Various IAP antagonists were reported to cooperate with 
TNF-related apoptosis inducing ligand (TRAIL; Apo2L) 
to kill carcinoma and leukemia cells in vitro and in vivo 
[26, 36-45]. The utility of some of these co-treatments 
are presently being assessed in clinical trials. In addition 
to hopefully offering robust anti-cancer efficacy, IAP 
antagonists lack the mutagenicity associated with DNA 
damaging chemotherapy [46], so they may spare cancer 
survivors the risk of developing therapy-related cancers.
In some cell types, exposure to IAP antagonists 
results in stimulation of non-canonical NF-κB pathways 
that promote induction of TNFα expression, which 
stimulates autocrine TNF-R1 signaling of apoptotic and/or 
necroptotic cell death [47]. IAP antagonists kill these cell 
types as sole agents. Other cell types fail to produce TNFα 
following treatment with IAP antagonists. IAP antagonists 
only kill these cells in the presence of exogenous TNFα 
produced by other surrounding cells in vivo, or provided 
experimentally in vitro [47]. Production of inflammatory 
cytokines such as TNFα by tumor associated macrophages 
can enhance the development and progression of various 
malignancies [48-50]. Recent evidence suggests that 
osteosarcoma may be a cancer type whose growth and 
spread is driven by TNFα. TNFα was reportedly required 
for osteosarcoma progression in mice [51]. Levels of 
TNFα were elevated in the blood of osteosarcoma patients, 
particularly those with large tumors [52, 53], and the 
local concentration at the tumor site would presumably 
be even higher. The observed overexpression of cIAP1/2 
in osteosarcomas [12] probably reflects selective pressure 
during tumorigenesis for TNFα to stimulate proliferation 
rather than cell death. Thus the presence of local TNFα 
probably promotes osteosarcoma expansion and invasion, 
but could also be exploited therapeutically, if it could 
cooperate with IAP antagonists to promote tumor cell 
death. 
Most research into the anti-cancer potential of IAP 
antagonists has focused on carcinomas and hematopoietic 
malignancies. Very little research has assessed their 
utility for sarcomas such as osteosarcoma. GDC-0152 
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was recently published to counter the pro-survival effects 
of Angiopoietin-like protein 2 on an established human 
osteosarcoma cell line, SaOS2 [54]. Human osteosarcoma 
xenografts grew somewhat slower in SCID mice treated 
with LCL161 than in untreated mice [55], although TNFα 
levels may be lower in SCID mice than wild type animals 
[56], so that study may have underestimated the ability 
of LCL161 to cooperate with host-derived TNFα to kill 
implanted tumor cells. 
In this study we characterized the anti-osteosarcoma 
activity of a panel of IAP antagonists, using cells derived 
using two spontaneous osteosarcoma mouse models. 
Fibroblastic osteosarcomas were isolated from mice 
in which the p53 and Rb genes were deleted from cells 
expressing the osteoblast marker Osterix [57], whereas 
osteoblastic osetosarcomas were harvested from animals 
following lineage-specific deletion of Rb coupled with sh-
RNA-mediated p53 downregulation [58].
results
sM-164, Gdc-0152 and lcl161 sensitize murine 
osteosarcoma cells to TNFα
Cells from osteoblastic (98Sc, 147H and 148I) and 
fibroblastic (493H, 494H and 1029H) primary tumors 
were incubated with six different IAP antagonists, with 
or without TRAIL or TNFα. None of the IAP antagonists 
were toxic to osteosarcoma cells as sole agents or in 
conjunction with TRAIL (Figure 1, Supp. Figure 1), 
Figure 1: SM-164, GDC-1052 and LCL161 sensitize osteosarcoma cells to TNFα but not TRAIL. Cells from the specified 
primary murine osteosarcomas were incubated for 48 h with the listed IAP antagonist drugs (IAD, colored columns) or media (black 
columns), together with murine TRAIL or TNFα, or no death ligand. ATP levels were measured with the CellTiterGlo reagent. Analyses of 
drug interactions and the significance of differences in treatment outcomes are provided in Supplementary Figure 2.
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Figure 2: SM-164 cooperates with low concentrations of TNFα to kill cells from some primary murine osteosarcomas. 
Cells from the specified primary murine osteosarcomas were incubated for 48 h with the listed concentrations of SM-164 (colored lines) or 
media (black columns) together with a range of concentrations of TNFα, or none. ATP levels were measured with the CellTiterGlo reagent. 
Analyses of drug interactions are provided in Supplementary Figure 3A.
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Figure 3: GDC-0152 cooperates with low concentrations of TNFα to kill cells from some primary murine osteosarcomas. 
Cells from the specified primary murine osteosarcomas were incubated for 48 h with the listed concentrations of GDC-0152 (colored lines) 
or media (black columns) together with a range of concentrations of TNFα, or none. ATP levels were measured with the CellTiterGlo 
reagent. Analyses of drug interactions are provided in Supplementary Figure 3B.
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however LCL161, GDC-0152 and SM-164 cooperated 
synergistically with TNFα to kill the murine osteosarcoma 
cells (Figure 1, Supp. Figure 2). Cells from some tumors 
were more sensitive to the combination treatment than 
others, but the responsiveness did not correlate with the 
tumor type (fibroblastic versus osteoblastic). 
The osteosarcoma cells were only sensitive to IAP 
antagonists as a co-treatment with TNFα. Use of TNFα 
as a therapeutic agent has been limited to isolated limb 
perfusion [59] due to serious toxicities such as hypotension 
and hepatotoxicity following systemic administration [60]. 
Therefore, clinical efficacy, particularly for metastatic 
cancers, would require sufficient endogenous TNFα at the 
tumor site to cooperate with exogenously administered 
IAP antagonists. Previous studies documented average 
TNFα levels in osteosarcoma patients’ blood to be 12 
[52] and 28 pg/ml [53]. These concentrations were 
about twice those in the blood of healthy individuals 
[52, 53], and patients with larger tumors had three-fold 
higher serum TNFα levels than controls [52]. Although 
the concentration of TNFα within osteosarcomas has not 
been reported, presumably the excess TNFα in the blood 
derives from the tumor site, implying that the intratumoral 
levels would be much higher. 
To define the levels of TNFα required for IAP 
antagonists to kill murine osteosarcoma cells, we 
performed dose titration experiments using TNFα and 
the most potent members of the panel of IAP antagonists: 
GDC-0152 and SM-164. To focus on physiologically 
achievable concentrations of the IAP antagonists, we set 
the upper limit of their concentrations at 10 µM, slightly 
higher than the GDC-0152 peak plasma concentration (7 
µM [24]). Pharmacokinetic data have not been published 
for SM-164, but the levels of LCL-161 [31] and Birinapant 
[61] detected in the blood of treated patients resembled 
those of GDC-0152, so it seems likely that SM-164 may 
also reach similar levels in vivo.
Both IAP antagonists cooperated with low 
concentrations of TNFα to kill the osteosarcoma cells 
(Figure 2, 3, Supp. Figure 3). The extent to which IAP 
antagonists sensitized cells from the different tumors 
to TNFα varied. Using ATP levels to monitor survival, 
cells from four tumors (98Sc, 493H, 494H and 1029H) 
were killed by levels of SM-164 or GDC-0152 that are 
likely to be physiologically achievable, coupled with 
concentrations of TNFα that were similar to or up to 
100-fold higher than those detected in the blood of 
osteosarcoma patients [53]. Cells from tumor 147H 
exhibited dose-dependent sensitivity to the combined 
treatment but higher concentrations of both agents were 
required to kill these cells. Cells from the 148I tumor 
were also relatively resistant: these cells responded to all 
concentrations of SM-164 or GDC-0152, but only when 
co-treated with high concentrations of TNFα. SM-164 
seemed to cooperate with TNFα slightly more strongly 
than GDC-0152 (Figure 2, 3), so the remainder of this 
study focused on SM-164.
To verify that the decrease in ATP levels observed 
following combined treatment with SM-164 and TNFα 
reflected abolition of clonogenic survival, we exposed 
Figure 4: Co-treatment with SM-164 and low concentrations of TNFα reduces the clonogenic survival of osteosarcoma 
cells. 98Sc, 1029H or 494H cells were grown in media containing no drugs or the indicated concentrations of TNFα and/or SM-164,. 
The drugs were either removed and replaced with normal media after 24h (left side) or replaced every 48 h (right side). The numbers of 
colonies that arose after these treatments were counted. Mean relative clonogenic survival and SEM are graphed from three independent 
experiments. Two-sided paired T-tests were used to calculate the probability that the observed differences between untreated cells and cells 
treated with TNFα plus SM-164 were due to chance. Analyses of the significance of differences between results from single and combined 
treatments, and raw data, are provided in Supplementary Tables 1 and 2. 
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primary tumor cells from three mice to a concentration 
of SM-164 likely to resemble the peak plasma level (5 
µM) together with a concentration of TNFα slightly lower 
than that reported in the blood of osteosarcoma patients 
(10 pg/ml). Clonogenic survival was monitored after a 24 
h exposure or after continuous exposure (replacing media 
containing or lacking the drugs every 48 h). Combined 
treatment for 24 h reduced the cells’ clonogenicity by 25-
40%, and extended exposure abolished the clonogenicity 
of the majority of the cells (Figure 4, Supp Tables 1, 2). 
Doxorubicin cooperates with IAP antagonists plus 
TNFα to kill osteosarcoma cells
Doxorubicin is a crucial component of multi-agent 
chemotherapy regimens for osteosarcoma patients [4]. 
We therefore explored whether SM-164 and TNFα could 
enhance the anti-osteosarcoma activity of doxorubicin. 
Cells from each of the tumors were incubated with no 
drugs, SM-164, TNFα or both, coupled with a range of 
doxorubicin concentrations up to that detected in the blood 
of treated cancer patients [62]. Increasing concentrations 
of doxorubicin enhanced the lethality mediated by co-
treatment with SM-164 plus TNFα (Figure 5). The 
magnitude of this cooperation was similar to that predicted 
for an additive interaction (Figure 5, Supp Figure 4). 
Sensitization of osteosarcoma cells to TNFα by 
IAP antagonists requires RIPK1
To explore the molecular basis for the heterogeneity 
in responses we observed between cells derived from 
different tumors, particularly the relative resistance of 
cells from tumors 147H and 148I, we surveyed expression 
of proteins previously implicated in cell death induced by 
IAP antagonists. Antagonism of IAP proteins can sensitize 
cells to TNFα-mediated apoptosis, which requires the 
“ripoptosome” components RIPK1, caspase-8 and 
FADD, and/or necroptosis, which typically involves the 
“necrosome” constituents RIPK1, RIPK3 and MLKL. 
The levels of surface and total expression of the receptor 
TNF-R1, and intracellular levels of FADD and caspases-8 
and -3 were no lower in the resistant cells than the sensitive 
ones (Figure 6A, 6B). Cells from each of the tumors 
expressed similar amounts of XIAP and cIAP1, and none 
expressed detectable levels of cIAP2 (Figure 6C-6E). SM-
164 treatment stimulated equally dramatic degradation of 
cIAP1 in cells from each of the osteosarcomas (Figure 6 
E). Interestingly, the two more resistant cell lines, 147H 
and 148I, expressed less RIPK1 than cells from the other 
tumors (Figure 6A). Cells from the 148I tumor also lacked 
any detectable RIPK3 expression and bore only low levels 
of MLKL (Figure 6A). 
Treating cells from the 98Sc tumor with SM-
164 and TNFα provoked DEVDase activity (Figure 
7A), which has been shown to predominantly reflect 
levels of active caspases-3, -7 and possibly -8 [63, 64]. 
The combined treatment also led to externalization of 
phosphatidyl serine, prior to disruption of the plasma 
membrane, similar to the classical caspase-dependent 
apoptosis provoked by exposure to Fas ligand (Figure 
7B). The lethality and DEVDase activity stimulated by 
SM-164/TNFα co-treatment were efficiently inhibited 
by necrostatin (Fig 7A, 7C, 7D), and downregulation of 
RIPK1 in 494H cells reduced the loss of ATP in these 
cells following co-treatment with SM-164 and TNFα (Fig 
7E, 7F). These data imply that SM-164/TNFα-induced 
death involved RIPK1-dependent activation of caspase-8 
and executioner caspases [65]. Pan-caspase inhibition 
by Q-VD-OPh [66] suppressed the DEVDase activity 
associated with SM-164/TNFα treatment (Figure 7A), 
but the caspase inhibitor slightly augmented rather than 
suppressed the death following the co-treatment (Figure 
7C, 7D). MLKL phosphorylation was markedly induced in 
cells treated with Q-VD-OPh before exposure to SM-164/
TNFα (Figure 7G), suggesting that necroptotic death was 
triggered by TNFα when IAPs and caspase were inhibited. 
Caspase-8 has been shown to suppress necroptosis [67, 
68], so presumably in this context Q-VD-OPh indirectly 
stimulated necroptosis by preventing the proteolysis of 
one or more pro-necroptotic substrates by caspase-8 [22]. 
RIPK1 has been proposed to be a key substrate whose 
cleavage by caspase-8 suppresses necroptosis [69-72], 
although evidence that RIPK1 is a poor caspase-8 substrate 
[73, 74] argues against this model. CYLD, an enzyme 
that de-ubiquitinates RIPK1 [75], was also reported to 
be a crucial substrate whose proteolysis by caspase-8 
inhibits necroptosis [76]. We failed to detect cleavage 
of either of these proteins in cells treated with SM-164/
TNFα, with or without prior Q-VD-OPh treatment (Figure 
7H). We therefore speculate that, in these osteosarcoma 
cells, TNFα/SM-164-induced necroptosis triggered by 
caspase inhibition resulted from suppression of caspase-
8-mediated cleavage of an as-yet unidentified substrate.
SM-164 sensitizes primary and metastatic 
osteosarcoma cells to TNFα
Metastatic osteosarcomas are particularly 
unresponsive to current therapies. One of the strengths 
of the genetically engineered murine osteosarcoma 
models used in this study is their ability to recapitulate 
the typical metastatic pattern of human osteosarcoma; 
primarily metastasizing to lung and less commonly to 
other sites including liver [57, 58, 77]. Most of the mice 
whose primary tumors were analyzed in the preceding 
experiments developed lung metastases (denoted by an 
“L” suffix) and one had a secondary tumor in its liver 
(#1029LV). We examined the sensitivity of cells from 
these secondary osteosarcomas to SM-164 and TNFα in 
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Figure 5: Doxorubicin cooperates with SM-164 and TNFα co-treatment to kill primary murine osteosarcoma cells. A. 
Osteosarcoma cells from the specified murine tumors were incubated in media containing no drugs, 1 µM SM-164 and/or 1 ng/ml TNFα 
with the indicated concentrations of doxorubicin for 48 h. ATP levels in the cells were then measured using the CellTiterGlo kit. B. 98Sc 
cells were incubated in media containing no drugs, 10 µM SM-164 and/or 1 ng/ml TNFα with the indicated concentrations of doxorubicin 
for 48 h, stained with Annexin-V-FITC to identify dead and dying cells, then analyzed by flow cytometry. (A, B) The green line shows 
the expected outcomes based on an additive interaction between SM-164/TNFα and doxorubicin, calculated using a fractional product 
approach. Means and SEM from three independent experiments are shown. Analyses of drug interactions are provided in Supplementary 
Figure 4.
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Figure 6: RIPK1 and RIPK3 levels vary between primary murine osteosarcomas. A. Cells from the specified tumors were lysed 
and subjected to SDS-PAGE, then immunoblotted with the indicated antibodies or subjected to Coomassie staining. B. Unpermeabilized 
cells were stained with anti-TNFR1 antibody (red lines) or anti-GFP (as a control; blue lines) followed by FITC-conjugated anti-rabbit, then 
analyzed by flow cytometry. The average specific mean fluorescence intensities (anti-TNFR1 minus anti-GFP) are stated (+/- SEM, from 
three experiments). C. To validate the specificity of the IAP family member antibodies, 293T cells were transfected with plasmids encoding 
the specified proteins or empty vector (pEF), then lysates were immunoblotted with the listed antibodies. D. Lysates from the osteosarcoma 
cells and 293T cells transfected with a cIAP2 expression plasmid were immunoblotted with an antibody recognizing cIAP2. E. Cells were 
incubated in media (UT) or 10 µM SM-164 (SM) for 45 min then lysed and subjected to immunoblotting with the listed antibodies.
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Figure 7: Co-treatment with SM-164 plus TNFα stimulates RIPK1-dependent apoptosis of 98Sc osteosarcoma cells. 
A. 98Sc cells were pre-treated with no inhibitor, Q-VD-OPh (to inhibit caspases) or necrostatin (to inhibit RIPK1) for 1 h, then additional 
media was added containing either no drugs, 1 ng/ml TNFα plus 1 µM SM-164, or 100 ng/ml FasL (all final concentrations). After 6 h, 
DEVDase (caspase) activity was measured. B. 98Sc cells were incubated with 1 ng/ml TNFα plus 1 µM SM-164 or 100 ng/ml FasL for the 
designated periods of time. The cells were stained with propidium iodide (PI) and Annexin-V-FITC to identify dead and dying cells and 
analyzed by flow cytometry. C. 98Sc cells were treated as outlined for panel A. After 6 h, cell death was monitored flow cytometrically 
after staining with Annexin-V-FITC and propidium iodide. D. 98Sc cells were treated as outlined for panel A. ATP levels, reflecting the 
proportion of surviving and metabolically active cells, were measured after 24 h. 494H cells were transfected with a non-targeting siRNA 
(NT) or an siRNA targeting RIPK1, or left untransfected (UT). Cells were harvested for anti-RIPK1 immunoblotting E. and for seeding 
into plates containing the specified concentrations of drugs. After 48 h, ATP levels were measured F. G.-I. 98Sc cells were lysed following 
6 h incubation in media or 1 ng/ml TNFα plus 10 µM SM-164, with or without 1 h pre-treatment with Q-VD-OPh. (G) Lysates were 
subjected to SDS-PAGE and immunoblotting with an antibody recognizing phospho-MLKL. The membrane was washed and probed with 
secondary antibody (to check for residual signal) before being probed with an antibody recognizing phosphorylated and unphosphorylated 
MLKL (and exposed for the same time as following probing only with secondary antibody). (H) Lysates were immunoblotted to detect 
RIPK1 or CYLD. Arrows indicate the expected migration of predicted cleavage products. (I) Lysate from untreated cells was incubated 
with recombinant caspase-8 at 37°C for 30 min before SDS-PAGE and immunoblotting to detect RIPK1. (A-D, F) Means and SEM are 
shown from three independent experiments. (A, C, D, F) P values are shown from two sided, paired t-tests, comparing the responses to the 
indicated treatments. 
Oncotarget33876www.impactjournals.com/oncotarget
parallel with cells from the matching primary tumors. 
Cells from all of the metastatic osteosarcomas were 
sensitive to the combination treatment (Figure 8, Supp. 
Table 3). Interestingly, however, cells from the lung 
metastasis in mouse #147 were more sensitive than cells 
from that animal’s primary tumor, whereas cells from 
the metastatic tumors from mice #98 and #1029 were 
somewhat less sensitive than cells from their primary 
tumors (Figure 8). These data suggest that TNFα signaling 
pathways changed during metastasis in these animals. 
However, osteosarcomas are highly penetrant in these 
genetically engineered mice, so it is also possible that 
some of the metastatic tumors arose independently, from 
a distinct primary cancer from that which we resected and 
analyzed. In contrast, cells from primary and metastatic 
tumors from each mouse generally exhibited similar 
sensitivity to doxorubicin and cisplatin, as measured by 
ATP levels (Figure 9, Supp Figure 5), although cisplatin 
exposure provoked a more substantial drop in ATP levels 
in cells from the metastatic tumor from mouse #98 than to 
those from its primary tumor (Figure 9).
Cells from the lung metastases 98L and 148L, which 
were relatively insensitive to SM-164/TNFα-induced death 
(Figure 8), expressed comparatively little RIPK1 (Figure 
10). Interestingly, RIPK3 levels varied considerably in 
cells from the metastatic osteosarcomas: 1029LV and 
493L expressed robust levels, 494L expressed less, and 
none was detected in lysates of cells from the metastatic 
tumors 98L, 147L or 148L (Figure 10). The RIPK3 levels 
did not correlate with sensitivity, however. Cells from the 
metastatic tumor 147L lacked RIPK3 expression, yet SM-
164 sensitized these cells to TNFα as efficiently as cells 
from the RIPK3-expressing tumors 493L and 1029LV. 
Necrostatin completely prevented or substantially reduced 
SM-164/TNFα-mediated death of cells from most of 
the tumors (Figure 8). Although necrostatin completely 
blocked the lethality to 98Sc cells of 1 µM SM-164 
plus 1 ng/ml of TNFα (Figure 7), it was less effective 
at suppressing death provoked by co-treatment of these 
highly responsive cells with 10 µM SM-164 coupled with 
100 pg/ml of TNFα (Figure 8). Necrostatin was also less 
active on cells expressing low levels of RIPK1 (from the 
primary tumor 148I and metastases 98L, 147L and 148L). 
Caspase inhibition by Q-VD-OPh failed to suppress SM-
164/TNFα-induced death in cells from any tumors.
Unlike doxorubicin, SM-164 does not provoke 
mutations in surviving cells
An emerging challenge in cancer treatment is 
minimizing the risk of survivors acquiring subsequent 
malignant neoplasms due to their exposure to DNA 
damaging chemotherapy or radiotherapy [78]. We 
previously found that the IAP antagonists LCL161 and 
DEBIO1143 (AT-406) were non-mutagenic [46], implying 
that they would lack the oncogenic potential of current 
anti-cancer drugs. To determine whether SM-164 also 
lacks mutagenic activity, we compared the ability of 
equivalently lethal concentrations of doxorubicin and 
SM-164 (alone or with a low concentration of TNFα) to 
provoke loss-of-function mutations in the HPRT locus 
of TK6 lymphoid cells. This assay capitalizes on the 
ability of active HPRT enzymes to convert the purine 
analog 6-thioguanine into a toxin, hence the clonogenicity 
of drug-treated TK6 cells grown in the presence of 
6-thioguanine provides a measure of the drug’s ability to 
induce mutations in the HPRT gene [79]. A concentration 
of doxorubicin that abolished the clonogenicity of around 
40% of the TK6 cells provoked frequent emergence of 
6-thioguanine resistant clones (implying HPRT mutations) 
(Figure 11). In contrast, a concentration of SM-164 that 
had a similar impact on clonogenicity failed to yield any 
more 6-thioguanine-resistant clones than no treatment. 
Addition of a physiologically-relevant concentration of 
TNFα did not affect clonogenicity or mutagenicity (Figure 
11). 
dIscussIon
IAP antagonists cooperated with low doses of TNFα 
to kill cells from most primary and metastatic murine 
osteosarcomas, suggesting that members of this class of 
drugs may be therapeutically useful anti-osteosarcoma 
agents. The cooperation we observed between SM-
164/TNFα and doxorubicin further suggests that IAP 
antagonists may augment the efficacy of currently used 
chemotherapy regimens, and/or could permit lower (safer) 
doses of chemotherapy drugs to be employed without 
compromising anti-tumor responses.
It was intriguing that the murine osteosarcoma 
cells survived combined treatment with TRAIL and IAP 
antagonists, despite expressing the death-promoting 
murine TRAIL receptor (Supp Figure 1). IAP antagonism 
was previously published to sensitize cells from breast, 
prostate, colon, urothelial, cervical, nasopharyngeal, 
bladder and pancreatic cancers, leukemias, neuroblastomas 
and gliomas to killing by TRAIL [26, 36, 38, 39, 43-
45, 80-85], so the resistance of osteosarcoma cells to 
this combined treatment is unusual. Further work will 
be required to determine the molecular basis for this 
resistance. Possible mechanisms could include expression 
of membrane-bound decoy receptors mDcTRAIL-R1/2 
[86] or the soluble decoy receptor osteoprotegerin (OPG), 
which is produced by osteoblasts [87] and osteosarcomas 
[88] and has been previously shown to protect 
osteosarcoma [89], breast cancer [90] and myeloma [91] 
cells from TRAIL-induced death.
The IAP antagonists that cooperated most strongly 
with TNFα to kill osteosarcoma cells efficiently targeted 
XIAP in addition to cIAP1 and 2. Treatment of the 
sensitive osteosarcoma cells with SM-164 plus TNFα 
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Figure 8: SM-164 sensitizes metastatic murine osteosarcoma cells to TNFα. A., C. Cells from primary (A) or metastatic (C) 
tumors were incubated in the media containing no drugs or a range of concentrations of SM-164 and/or TNFα for 48 h, then ATP levels were 
measured. B., D. Cells from the specified primary (B) or metastatic (D) tumors were pre-treated with no inhibitor, 10 µM of Q-VD-OPh (to 
inhibit caspases) or 10 µM necrostatin (to inhibit RIPK1) for 1 h, then additional media was added containing either no drugs or SM-164 
plus TNFα. Ten micromolar SM-164 was used for cells from all tumors. TNFα was used at 1 ng/ml for the more resistant cells (147H and 
148I) and 100 pg/ml for the remainder. ATP levels, reflecting the proportion of surviving and metabolically active cells were measured after 
48 h. Means and SEM are shown from three independent experiments.
Oncotarget33878www.impactjournals.com/oncotarget
Figure 9: Doxorubicin and cisplatin kill murine primary and metastatic osteosarcoma cells. Osteosarcoma cells from 
murine early passage cell lines derived from primary or metastatic tumors from the numbered mice were incubated in the media containing 
no drugs or the indicated concentrations of doxorubicin or cisplatin for 48 h, then ATP levels were measured. Analyses of the significance 
of differences in sensitivity of cells from primary and metastatic tumors are provided in Supplementary Figure 5.
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Figure 10: RIPK1 and RIPK3 levels vary between primary and metastatic murine osteosarcomas. Cells from the specified 
tumors were lysed and subjected to SDS-PAGE, then immunoblotted with the indicated antibodies or subjected to Coomassie staining. 
Figure 11: SM-164 does not induce mutations at the HPRT locus of TK6 cells. TK6 cells were incubated for 24 h with no drug, 
5 nM doxorubicin (dox), 15 µM SM-164 (SM) or 15 µM SM-164 plus 5 pg/ml TNFα (SM+T). Clonogenic survival was determined (left 
bars) or the cells were seeded in 96-well plates containing or lacking 6-thioguanine to determine the HPRT mutation frequency (right bars). 
Means and SEM from three independent experiments are shown.
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provoked rapid DEVDase activity and exposure of 
phosphatidyl serine, followed by subsequent plasma 
membrane disruption. The responsive cells could be 
protected by pre-treatment with necrostatin, and cells 
from some of the sensitive osteosarcomas expressed little 
or no RIPK3. Together these observations suggest that, 
for TNFα to kill osteosarcoma cells, RIPK1 is required 
and the activities of cIAP1 and XIAP must be diminished. 
We infer that, in osteosarcoma cells, IAP antagonist-
mediated degradation of cIAP1 enables formation of 
the ripoptosome and activation of caspase-8, which can 
stimulate caspase-3/7 activity if the IAP antagonist permits 
this by relieving XIAP-mediated inhibition. Presumably 
Birinapant and DEBIO1143/AT-406 were less effective 
because they target XIAP less efficiently than SM-164, 
GDC-0152 and LCL161. BV6 appears to represent an 
exception to this rule: its affinity for XIAP was reportedly 
only around three-fold lower than for cIAP1 [27] yet it 
was the least potent IAP antagonist of those tested in 
this study. It is possible that this surprisingly marginal 
impact of BV6 plus TNFα reflects less efficient uptake of 
BV6 than the other drugs, rather than differences in their 
biochemical activities.
RIPK1 expression levels predicted sensitivity to 
IAP antagonist/TNFα-induced death in cells from the 
different tumors. Necrostatin reduced or abolished the 
lethality triggered by treatment of osteosarcoma cells 
with IAP antagonists plus TNFα, implying that RIPK1 is 
required for this cell death. In contrast, caspase inhibition 
(by Q-VD-OPh) failed to protect these cells from IAP 
antagonist/ TNFα-mediated death. Phosphorylation of 
MLKL in 98Sc cells under these conditions suggests 
that inhibition of caspases (probably caspase-8) switched 
signaling from ripoptotic to necroptotic cell death, 
consistent with previous reports [67, 68]. We were however 
surprised to note that caspase inhibition was ineffectual 
even in cells lacking RIPK3, the kinase proposed to be 
responsible for MLKL phosphorylation [92]. Cells from 
one primary and three secondary tumors lacked detectable 
RIPK3 expression, however this did not prevent their 
killing by treatment with IAP antagonists and TNFα. Cells 
from the 147L lung metastasis, which expressed robust 
levels of RIPK1 but no RIPK3, were as sensitive as cells 
from other tumors that expressed similar levels of RIPK1 
and high levels of RIPK3. Q-VD-OPh slightly enhanced 
the sensitivity of some cells to SM-164/TNFα, and had 
negligible effects on others. In contrast, necrostatin 
markedly reduced the sensitivity of cells from all tumors. 
Thus, our data suggest that although IAP antagonist/
TNFα treatment of osteosarcoma cells normally leads to 
ripoptosome-mediated apoptosis, suppression of caspase 
activity in osteosarcoma cells treated with these agents 
provokes cell death that is primarily RIPK1-dependent but 
does not necessarily require RIPK3. A similar observation 
was recently reported in murine fibrosarcoma cells [93]. 
Necrostatin failed to protect primary or metastatic cells 
from mouse #148 from death caused by treatment with 
high doses of SM-164 and TNFα. These cells lacked 
RIPK3 and expressed low levels of RIPK1, and were 
relatively unresponsive to IAP antagonists plus TNFα. 
These data suggest that high doses of SM-164 plus TNFα 
can reduce the survival of cells from this tumor through 
pathways that are independent of caspases, RIPK1 and 
RIPK3, but because high concentrations of drugs were 
required to stimulate this death in vitro, such alternative 
pathways may not occur in vivo. 
The ability of necrostatin to protect sensitive 
osteosarcoma cells from death triggered by co-treatment 
with IAP antagonists plus TNFα imply that RIPK1 is an 
important determinant of sensitivity. Consistent with this, 
the less sensitive osteosarcoma cell lines expressed lower 
levels of RIPK1. If the results of this study translate to 
human osteosarcomas, the levels of TNFα and RIPK1 
in patients’ tumors may predict their responses to 
treatment with pan-specific IAP antagonists. Because IAP 
antagonists including SM-164 are non-mutagenic, we 
expect that they would be less likely than DNA-damaging 
chemotherapy drugs to stimulate therapy-induced cancers 
in cured osteosarcoma patients.
MAterIAls And Methods
reagents
Drugs used in this study were recombinant murine 
sTRAIL/Apo2L (Peprotech; NJ, USA), murine TNFα 
(Peprotech), Debio1143/AT-406 (Selleck Chemicals; 
Texas, USA), LCL161 (Selleck Chemicals), SM-164 
(ApexBio; Texas, USA), Birinapant (ApexBio), BV6 
(ApexBio), GDC-0512 (Selleck), doxorubicin (Sigma-
Aldrich; MO, USA) and cisplatin (Sigma-Aldrich). 
The following antibodies were used: anti-cIAP1 (Enzo 
Life sciences; NY, USA) , anti-cIAP2 (R&D systems; 
MN, USA), anti-XIAP (MBL International; MA, 
USA), anti-FADD (Abcam; Cambridge, UK), anti-
TNFR1 (Abcam), anti-TRAIL-R2 (R&D systems), anti-
caspase-3 (BD Biosciences; NJ, USA), anti-caspase-8 
(Abcam), anti-RIPK1 (BD Biosciences), anti-RIPK3 
(ProSci; CA, USA), anti-MLKL1 (Abcam), anti-
phosphoS345-MLKL (Abcam), anti-CYLD (Thermo 
Fisher Scientific; Massachusetts, USA), anti-crmA (Santa 
Cruz Biotechnology; Texas, USA), rabbit anti-GFP 
(polyclonal in-house antibody), goat anti-rabbit FITC 
(Merck Millipore; MA, USA), rabbit anti-goat-FITC 
(Thermo Fisher Scientific), mouse anti-GAPDH (Merck 
Millipore), donkey anti-rabbit HRP conjugated antibody 
(GE Healthcare Life Sciences; NJ, USA), goat anti-rat 
HRP conjugated antibody (GE Healthcare Life Sciences), 
and rabbit anti-mouse-HRP conjugated antibody (Sigma).
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Animals and cells
Spontaneous fibroblastic primary and metastatic 
osteosarcomas were obtained from Osx-Cre p53fl/fl pRbfl/
fl mice [57]. Osteoblastic osteosarcomas were harvested 
from Osx-Cre TRE-p53.1224 pRb fl/fl mice [58]. Cells were 
isolated from the tumors by dissociation with a scalpel and 
cultured from these tumors as described previously [94], 
and used within 14 ex vivo passages. TK6 cells [95] were 
obtained from ATCC (Manassas, Virginia, USA) and were 
grown in RPMI (Invitrogen; CA, USA) containing 10 % 
heat inactivated FBS. L929 cells (a kind gift from Wendy 
Cook and David Vaux), HEK-293T cells and LN18 cells 
and were cultured in Dulbecco’s modified Eagle medium 
with high glucose (Invitrogen) supplemented with 10 % 
heat inactivated FBS. All cells were grown at 37 °C in air 
supplemented with 5 % CO2.
Cell death and caspase assays
For clonogenicity assays, one hundred thousand 
cells were plated per well of a 24-well plate and incubated 
with drugs or normal media for the specified times, then 
washed once with phosphate buffered saline (PBS; Astral 
Scientific; Tarren Point, NSW, Australia) and plated at 
various densities in 6-well plates. After seven days (494H) 
or ten days (98Sc and 1029H) or fourteen days (147H and 
148I), cells were stained with methylene blue (Sigma-
Aldrich; 1.25 g/l in 50 % methanol) for 5 min, washed 
twice with water, and then the numbers of colonies were 
counted.
For acute cell death experiments, cells incubated 
with drugs or media were harvested, washed once with 
PBS, then resuspended in binding buffer (10 mM Hepes, 
140 mM NaCl, 2.5 mM CaCl2; pH 7.4) containing 1:250 
of Annexin-V-FITC (Abcam). After incubating the cells 
at 4 °C for 15 min, an equal amount of binding buffer 
containing 2 µg/ml propidium iodide (Sigma-Aldrich) 
was added before analysis. Cells were analyzed by flow 
cytometry for propidium iodide and/or Annexin-V-FITC 
positive cells using FACS Canto II (BD Biosciences). 
In some experiments cells were pre-treated for 1 h with 
10 µM of the pan-caspase inhibitor Q-VD-OPh (R&D 
systems) or the RIPK1 inhibitor necrostatin-1 (Sigma-
Aldrich).
The amount of ATP or DEVDase activity in cells 
upon treatment were determined using CellTiter-Glo 2.0 
or Caspase-Glo 3/7 assay kits respectively (Promega; 
WI, USA). Two thousand cells per well were plated in 
96-well white plates containing desired drugs or media to 
a final volume of 75 µl, and incubated for specified time. 
In some experiments cells were pre-treated for 1 h with 
10 µM of Q-VD-OPh (R&D systems) or necrostatin-1 
(Sigma-Aldrich). After treatment, 75 µl of CellTiter-Glo 
or Caspase-Glo 3/7 solution was mixed into each well. 
The plates were incubated at room temperature for 10 
min (CellTitre-Glo) or 30 min (Caspase-Glo3/7) then 
luminescence was recorded using a Spectromax M5 
(Molecular Devices; CA, USA).
transfections
HEK-293T cells were seeded into 6-well plates 
(3 x 105 cells per well) for transfection on the following 
day. Cells were transfected using Lipofectamine 2000 
(Thermo Fisher Scientific) with previously published 
plasmids [96], and then harvested 24 h post-transfection 
for immunoblotting. For siRNA transfections, 494H cells 
were seeded into 6-well plate (1.6 x 104 cells per well) 
in antibiotic free media. The following day cells in each 
well were transfected with 50 nM of On-Targetplus non-
targeting siRNA #2 (Thermo Fisher Scientific) or SMART 
pool: On-Targetplus mouse RIPK1 siRNA (Thermo Fisher 
Scientific) using 2 µl of DharmaFECT-2 transfection 
reagent (Thermo Fisher Scientific). Cells were incubated 
with transfection mixture for 8 h, before replacing 
media. Transfected cells were cultured for 48 h, and then 
harvested for immunoblotting and cell death assays.
Flow cytometry
Expression of TNFR1 or TRAIL-R2 on the 
surface of murine osteosarcoma cells was determined 
by flow cytometry. Cells were harvested and fixed in 4 
% paraformaldehyde (Sigma-Aldrich) for 15 min at 4 
°C. Fixed cells were washed with PBS containing 4 % 
FBS (PFS), then resuspended in 100 µl of PFS containing 
anti-TNFR1 antibody (or equivalent concentration of anti-
GFP antibody as an isotype control), or anti-TRAIL-R2 
antibody (or equivalent concentration of anti-crmA as an 
isotype control). Samples were incubated, rotating, at 4 
°C overnight, followed by washing twice with PFS and 
incubating with 100 µl of PFS containing FITC-conjugated 
secondary antibody for 1 h at room temperature, rotating. 
Samples were washed twice with PFS and FITC positive 
cell populations were determined using a FACS Canto II 
(BD Biosciences).
Cell lysis, electrophoresis and immunoblotting
Cell samples were lysed using RIPA lysis buffer 
(150 mM sodium chloride, 1.0 % Triton X-100, 0.5 % 
sodium deoxycholate, 0.1 % SDS, 50 mM Tris, pH 8.0) 
supplemented with protease inhibitor cocktail (Roche; 
Basel, Switzerland), then forced 10 times through a 
23-gauge needle to shear the DNA. The lysates were 
cleared by centrifuging for 15 min at 16,100 g at 4 °C. 
Total protein was determined using the bicinchoninic acid 
(BCA) method (Micro BCA Protein assay kit, Thermo 
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Fisher Scientific; IL, USA). Thirty to forty micrograms of 
lysates were loaded on Tris-glycine gels and the proteins 
were separated by sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis. The proteins were then either 
stained with coomassie stain followed by de-staining, 
or transferred onto Hybond PVDF 0.22 µm membrane 
(Millenium Science; Victoria Australia), blocked with 1% 
blocking reagent (Roche) in phosphate-buffered saline 
(PBS), and probed with primary antibodies in 1% blocking 
reagent (Roche) in PBS with 0.1% Tween-20 (Sigma-
Aldrich). Horseradish peroxidase (HRP)-conjugated 
secondary antibodies were detected using SuperSignal 
West Dura extended duration substrate (Thermo Fisher 
Scientific).
Mutagenesis
HPRT mutagenesis was performed as previously 
described [42] except that 2x104 cells were seeded per well 
in 96 well plates the presence of 30 µM 6-thioguanine.
GRANT SUPPORT
This study was funded by La Trobe University 
postgraduate scholarships to T.M.S. and M.A.M, an 
Australasian Sarcoma Study Group grant from the Leon 
Stone Memorial fund, an ASSG GPA Andrew Ursini 
Sarcoma Research Grant, an Australian Research Council 
Future Fellowship (#FT0991464) to C.J.H. and a grant 
from the Zig Inge Foundation to C.R.W.
conflIcts of Interest
The authors have no conflicts of interest.
references
1. Mirabello L, Troisi RJ and Savage SA. Osteosarcoma 
incidence and survival rates from 1973 to 2004: data from 
the Surveillance, Epidemiology, and End Results Program. 
Cancer. 2009; 115:1531-1543. doi: 1510.1002/cncr.24121.
2. Allison DC, Carney SC, Ahlmann ER, Hendifar A, Chawla 
S, Fedenko A, Angeles C and Menendez LR. A meta-
analysis of osteosarcoma outcomes in the modern medical 
era. Sarcoma. 2012; 2012:704872.
3. Nagarajan R, Kamruzzaman A, Ness KK, Marchese VG, 
Sklar C, Mertens A, Yasui Y, Robison LL and Marina 
N. Twenty years of follow-up of survivors of childhood 
osteosarcoma: a report from the Childhood Cancer Survivor 
Study. Cancer. 2011; 117:625-634.
4. Isakoff MS, Bielack SS, Meltzer P and Gorlick R. 
Osteosarcoma: Current Treatment and a Collaborative 
Pathway to Success. J Clin Oncol. 2015; 33:3029-3035.
5. Janeway KA and Grier HE. Sequelae of osteosarcoma 
medical therapy: a review of rare acute toxicities and late 
effects. Lancet Oncol. 2010; 11:670-678.
6. Lee JS, DuBois SG, Boscardin WJ, Wustrack RL and 
Goldsby RE. Secondary malignant neoplasms among 
children, adolescents, and young adults with osteosarcoma. 
Cancer. 2014; 120:3987-3993.
7. Deveraux Q, Roy N, Stennicke H, Van Arsdale T, Zhou 
Q, Srinivasula S, Alnemri E, Salvesen G and Reed J. 
IAPs block apoptotic events induced by caspase-8 and 
cytochrome c by direct inhibition of distinct caspases. 
EMBO J. 1998; 17:2215-2223.
8. Eckelman BP, Salvesen GS and Scott FL. Human inhibitor 
of apoptosis proteins: why XIAP is the black sheep of the 
family. EMBO Rep. 2006; 7:988-994.
9. Varfolomeev E, Goncharov T and Vucic D. Roles of c-IAP 
proteins in TNF receptor family activation of NF-kappaB 
signaling. Methods Mol Biol. 2015; 1280:269-282.
10. Hayden MS and Ghosh S. Regulation of NF-kappaB by 
TNF family cytokines. Semin Immunol. 2014; 26:253-266.
11. Kocab AJ and Duckett CS. Inhibitor of apoptosis proteins 
as intracellular signaling intermediates. Febs J. 2015; 
13:13554.
12. Ma O, Cai WW, Zender L, Dayaram T, Shen J, Herron 
AJ, Lowe SW, Man TK, Lau CC and Donehower LA. 
MMP13, Birc2 (cIAP1), and Birc3 (cIAP2), amplified on 
chromosome 9, collaborate with p53 deficiency in mouse 
osteosarcoma progression. Cancer Res. 2009; 69:2559-
2567.
13. Christofferson DE, Li Y and Yuan J. Control of life-or-
death decisions by RIP1 kinase. Annu Rev Physiol. 2014; 
76:129-150.
14. Du C, Fang M, Li Y, Li L and Wang X. Smac, a 
mitochondrial protein that promotes cytochrome 
c-dependent caspase activation by eliminating IAP 
inhibition. Cell. 2000; 102:33-42.
15. Verhagen AM, Ekert PG, Pakusch M, Silke J, Connolly 
LM, Reid GE, Moritz RL, Simpson RJ and Vaux DL. 
Identification of DIABLO, a mammalian protein that 
promotes apoptosis by bnding to and antagonizing IAP 
proteins. Cell. 2000; 102:43-53.
16. Fulda S and Vucic D. Targeting IAP proteins for therapeutic 
intervention in cancer. Nat Rev Drug Discov. 2012; 11:109-
124.
17. Schilling R, Geserick P and Leverkus M. Characterization 
of the ripoptosome and its components: implications for 
anti-inflammatory and cancer therapy. Methods Enzymol. 
2014; 545:83-102.
18. Pasparakis M and Vandenabeele P. Necroptosis and its role 
in inflammation. Nature. 2015; 517:311-320.
19. de Almagro MC and Vucic D. Necroptosis: Pathway 
diversity and characteristics. Semin Cell Dev Biol. 2015; 
39:56-62.
20. Murphy JM, Czabotar PE, Hildebrand JM, Lucet IS, Zhang 
J-G, Alvarez-Diaz S, Lewis R, Lalaoui N, Metcalf D, Webb 
Oncotarget33883www.impactjournals.com/oncotarget
AI, Young SN, Varghese LN, Tannahill GM, Hatchell EC, 
Majewski IJ, Okamoto T, et al. The Pseudokinase MLKL 
Mediates Necroptosis via a Molecular Switch Mechanism. 
Immunity. 2013; 39:443-453.
21. McQuade T, Cho Y and Chan FK. Positive and negative 
phosphorylation regulates RIP1- and RIP3-induced 
programmed necrosis. Biochem J. 2013; 456:409-415.
22. Salvesen GS and Walsh CM. Functions of caspase 8: the 
identified and the mysterious. Semin Immunol. 2014; 
26:246-252.
23. Cai Q, Sun H, Peng Y, Lu J, Nikolovska-Coleska Z, 
McEachern D, Liu L, Qiu S, Yang CY, Miller R, Yi H, 
Zhang T, Sun D, Kang S, Guo M, Leopold L, et al. A 
potent and orally active antagonist (SM-406/AT-406) of 
multiple inhibitor of apoptosis proteins (IAPs) in clinical 
development for cancer treatment. J Med Chem. 2011; 
54:2714-2726.
24. Flygare JA, Beresini M, Budha N, Chan H, Chan IT, Cheeti 
S, Cohen F, Deshayes K, Doerner K, Eckhardt SG, Elliott 
LO, Feng B, Franklin MC, Reisner SF, Gazzard L, Halladay 
J, et al. Discovery of a potent small-molecule antagonist of 
inhibitor of apoptosis (IAP) proteins and clinical candidate 
for the treatment of cancer (GDC-0152). J Med Chem. 
2012; 55:4101-4113. .
25. Weisberg E, Ray A, Barrett R, Nelson E, Christie AL, 
Porter D, Straub C, Zawel L, Daley JF, Lazo-Kallanian S, 
Stone R, Galinsky I, Frank D, Kung AL and Griffin JD. 
Smac mimetics: implications for enhancement of targeted 
therapies in leukemia. Leukemia. 2010; 24:2100-2109.
26. Allensworth JL, Sauer SJ, Lyerly HK, Morse MA and 
Devi GR. Smac mimetic Birinapant induces apoptosis and 
enhances TRAIL potency in inflammatory breast cancer 
cells in an IAP-dependent and TNF-alpha-independent 
mechanism. Breast Cancer Res Treat. 2013; 137:359-371.
27. Varfolomeev E, Blankenship JW, Wayson SM, Fedorova 
AV, Kayagaki N, Garg P, Zobel K, Dynek JN, Elliott LO, 
Wallweber HJ, Flygare JA, Fairbrother WJ, Deshayes 
K, Dixit VM and Vucic D. IAP antagonists induce 
autoubiquitination of c-IAPs, NF-kappaB activation, and 
TNFalpha-dependent apoptosis. Cell. 2007; 131:669-681.
28. Lu J, Bai L, Sun H, Nikolovska-Coleska Z, McEachern D, 
Qiu S, Miller RS, Yi H, Shangary S, Sun Y, Meagher JL, 
Stuckey JA and Wang S. SM-164: a novel, bivalent Smac 
mimetic that induces apoptosis and tumor regression by 
concurrent removal of the blockade of cIAP-1/2 and XIAP. 
Cancer Res. 2008; 68:9384-9393.
29. Fulda S. Promises and Challenges of Smac Mimetics as 
Cancer Therapeutics. Clin Cancer Res. 2015; 21:5030-
5036.
30. Zawel L, Straub C, Firestone B, Sullivan J, Levine K, Porter 
D, Conway C, Yang G, Gao H, He D, Slisz J, Morrissey M, 
Monahan J, Mosher R, Stegmeier F, He F, et al. Therapeutic 
targeting of inhibitor of apoptosis proteins. Proceedings of 
the 101st Annual Meeting of the American Association for 
Cancer Research Abstract 138. Cancer Research. 2010; 
70:Abstr #138.
31. Infante JR, Dees EC, Olszanski AJ, Dhuria SV, Sen S, 
Cameron S and Cohen RB. Phase I Dose-Escalation 
Study of LCL161, an Oral Inhibitor of Apoptosis Proteins 
Inhibitor, in Patients With Advanced Solid Tumors. J Clin 
Oncol. 2014; 32:3103-3110.
32. DiPersio JF, Erba HP, Larson RA, Luger SM, Tallman 
MS, Brill JM, Vuagniaux G, Rouits E, Sorensen JM and 
Zanna C. Oral Debio1143 (AT406), an antagonist of 
inhibitor of apoptosis proteins, combined with daunorubicin 
and cytarabine in patients with poor-risk acute myeloid 
leukemia—results of a phase I dose-escalation study. Clin 
Lymphoma Myeloma Leuk. 2015; 15:443-449.
33. Carter BZ, Mak PY, Mak DH, Shi Y, Qiu Y, Bogenberger 
JM, Mu H, Tibes R, Yao H, Coombes KR, Jacamo RO, 
McQueen T, Kornblau SM and Andreeff M. Synergistic 
targeting of AML stem/progenitor cells with IAP antagonist 
birinapant and demethylating agents. J Natl Cancer Inst. 
2014; 106:djt440. .
34. Steinwascher S, Nugues AL, Schoeneberger H and Fulda S. 
Identification of a novel synergistic induction of cell death 
by Smac mimetic and HDAC inhibitors in acute myeloid 
leukemia cells. Cancer Lett. 2015; 366:32-43.
35. Steinhart L, Belz K and Fulda S. Smac mimetic and 
demethylating agents synergistically trigger cell death 
in acute myeloid leukemia cells and overcome apoptosis 
resistance by inducing necroptosis. Cell Death Dis. 2013; 
4:e802.
36. Wu MS, Wang GF, Zhao ZQ, Liang Y, Wang HB, Wu MY, 
Min P, Chen LZ, Feng QS, Bei JX, Zeng YX and Yang 
D. Smac mimetics in combination with TRAIL selectively 
target cancer stem cells in nasopharyngeal carcinoma. Mol 
Cancer Ther. 2013; 12:1728-1737.
37. Zhang S, Li G, Zhao Y, Liu G, Wang Y, Ma X, Li D, Wu 
Y and Lu J. Smac mimetic SM-164 potentiates APO2L/
TRAIL- and doxorubicin-mediated anticancer activity in 
human hepatocellular carcinoma cells. PLoS One. 2012; 
7:e51461. .
38. Lu J, McEachern D, Sun H, Bai L, Peng Y, Qiu S, Miller 
R, Liao J, Yi H, Liu M, Bellail A, Hao C, Sun SY, Ting 
AT and Wang S. Therapeutic Potential and Molecular 
Mechanism of a Novel, Potent, Nonpeptide, Smac Mimetic 
SM-164 in Combination with TRAIL for Cancer Treatment. 
Mol Cancer Ther. 2011; 10:902-914.
39. Metwalli AR, Khanbolooki S, Jinesh G, Sundi D, Shah 
JB, Shrader M, Choi W, Lashinger LM, Chunduru S, 
McConkey DJ, McKinlay M and Kamat AM. Smac mimetic 
reverses resistance to TRAIL and chemotherapy in human 
urothelial cancer cells. Cancer Biol Ther. 2010; 10:885-892.
40. Lecis D, Drago C, Manzoni L, Seneci P, Scolastico 
C, Mastrangelo E, Bolognesi M, Anichini A, Kashkar 
H, Walczak H and Delia D. Novel SMAC-mimetics 
synergistically stimulate melanoma cell death in 
combination with TRAIL and Bortezomib. Br J Cancer. 
2010; 102:1707-1716.
Oncotarget33884www.impactjournals.com/oncotarget
41. Fingas CD, Blechacz BR, Smoot RL, Guicciardi ME, Mott 
J, Bronk SF, Werneburg NW, Sirica AE and Gores GJ. 
A smac mimetic reduces TNF related apoptosis inducing 
ligand (TRAIL)-induced invasion and metastasis of 
cholangiocarcinoma cells. Hepatology. 2010; 52:550-561.
42. Vogler M, Walczak H, Stadel D, Haas TL, Genze F, 
Jovanovic M, Bhanot U, Hasel C, Moller P, Gschwend JE, 
Simmet T, Debatin KM and Fulda S. Small molecule XIAP 
inhibitors enhance TRAIL-induced apoptosis and antitumor 
activity in preclinical models of pancreatic carcinoma. 
Cancer Res. 2009; 69:2425-2434.
43. Dai Y, Liu M, Tang W, Li Y, Lian J, Lawrence TS and 
Xu L. A Smac-mimetic sensitizes prostate cancer cells to 
TRAIL-induced apoptosis via modulating both IAPs and 
NF-kappaB. BMC Cancer. 2009; 9:392.
44. Vogler M, Walczak H, Stadel D, Haas TL, Genze F, 
Jovanovic M, Gschwend JE, Simmet T, Debatin KM 
and Fulda S. Targeting XIAP bypasses Bcl-2-mediated 
resistance to TRAIL and cooperates with TRAIL to 
suppress pancreatic cancer growth in vitro and in vivo. 
Cancer Res. 2008; 68:7956-7965.
45. Li L, Thomas RM, Suzuki H, De Brabander JK, Wang X 
and Harran PG. A small molecule Smac mimic potentiates 
TRAIL- and TNFalpha-mediated cell death. Science. 2004; 
305:1471-1474.
46. Shekhar TM, Green MM, Rayner DM, Miles MA, Cutts SM 
and Hawkins CJ. Inhibition of Bcl-2 or IAP proteins does 
not provoke mutations in surviving cells. Mutat Res. 2015; 
777:23-32.
47. Silke J and Vucic D. IAP family of cell death and signaling 
regulators. Methods Enzymol. 2014; 545(doi):35-65.
48. Hanahan D and Weinberg RA. Hallmarks of cancer: the 
next generation. Cell. 2011; 144:646-674.
49. Grivennikov SI and Karin M. Inflammatory cytokines in 
cancer: tumour necrosis factor and interleukin 6 take the 
stage. Ann Rheum Dis. 2011; 70:i104-108.
50. Sethi G, Sung B and Aggarwal BB. TNF: a master switch 
for inflammation to cancer. Front Biosci. 2008; 13:5094-
5107.
51. Mori T, Sato Y, Miyamoto K, Kobayashi T, Shimizu T, 
Kanagawa H, Katsuyama E, Fujie A, Hao W, Tando 
T, Iwasaki R, Kawana H, Morioka H, Matsumoto 
M, Saya H, Toyama Y, et al. TNFalpha promotes 
osteosarcoma progression by maintaining tumor cells in an 
undifferentiated state. Oncogene. 2014; 33:4236-4241.
52. Xiao H, Chen L, Luo G, Son H, Prectoni JH and Zheng 
W. Effect of the cytokine levels in serum on osteosarcoma. 
Tumour Biol. 2014; 35:1023-1028.
53. Savitskaya YA, Rico-Martinez G, Linares-Gonzalez LM, 
Delgado-Cedillo EA, Tellez-Gastelum R, Alfaro-Rodriguez 
AB, Redon-Tavera A and Ibarra-Ponce de Leon JC. Serum 
tumor markers in pediatric osteosarcoma: a summary 
review. Clin Sarcoma Res. 2012; 2.
54. Yang L, Shu T, Liang Y, Gu W, Wang C, Song X, Fan 
C and Wang W. GDC-0152 attenuates the malignant 
progression of osteosarcoma promoted by ANGPTL2 via 
PI3K/AKT but not p38MAPK signaling pathway. Int J 
Oncol. 2015; 46:1651-1658. doi: 1610.3892/ijo.2015.2872. 
Epub 2015 Feb 1654.
55. Houghton PJ, Kang MH, Reynolds CP, Morton CL, Kolb 
EA, Gorlick R, Keir ST, Carol H, Lock R, Maris JM, 
Billups CA and Smith MA. Initial testing (Stage 1) of 
LCL161, a SMAC mimetic, by the pediatric preclinical 
testing program. Pediatr Blood Cancer. 2011; 58:636-639.
56. Choudhury HR, Sheikh NA, Bancroft GJ, Katz DR and 
De Souza JB. Early nonspecific immune responses and 
immunity to blood-stage nonlethal Plasmodium yoelii 
malaria. Infect Immun. 2000; 68:6127-6132.
57. Walkley CR, Qudsi R, Sankaran VG, Perry JA, Gostissa 
M, Roth SI, Rodda SJ, Snay E, Dunning P, Fahey FH, 
Alt FW, McMahon AP and Orkin SH. Conditional mouse 
osteosarcoma, dependent on p53 loss and potentiated by 
loss of Rb, mimics the human disease. Genes Dev. 2008; 
22:1662-1676.
58. Mutsaers AJ, Ng AJ, Baker EK, Russell MR, Chalk 
AM, Wall M, Liddicoat BJ, Ho PW, Slavin JL, Goradia 
A, Martin TJ, Purton LE, Dickins RA and Walkley CR. 
Modeling distinct osteosarcoma subtypes in vivo using 
Cre:lox and lineage-restricted transgenic shRNA. Bone. 
2013; 55:166-178.
59. Grunhagen DJ, de Wilt JH, ten Hagen TL and Eggermont 
AM. Technology insight: Utility of TNF-alpha-based 
isolated limb perfusion to avoid amputation of irresectable 
tumors of the extremities. Nat Clin Pract Oncol. 2006; 3:94-
103.
60. Roberts NJ, Zhou S, Diaz LA, Jr. and Holdhoff M. Systemic 
use of tumor necrosis factor alpha as an anticancer agent. 
Oncotarget. 2011; 2:739-751. doi: 10.18632/oncotarget.344.
61. Noonan AM, Bunch KP, Chen JQ, Herrmann MA, Lee JM, 
Kohn EC, O’Sullivan CC, Jordan E, Houston N, Takebe N, 
Kinders RJ, Cao L, Peer CJ, Figg WD and Annunziata CM. 
Pharmacodynamic markers and clinical results from the 
phase 2 study of the SMAC mimetic birinapant in women 
with relapsed platinum-resistant or -refractory epithelial 
ovarian cancer. Cancer. 2015; 13:29783.
62. Brana I, Ocana A, Chen EX, Razak AR, Haines C, Lee 
C, Douglas S, Wang L, Siu LL, Tannock IF and Bedard 
PL. A phase I trial of pantoprazole in combination with 
doxorubicin in patients with advanced solid tumors: 
evaluation of pharmacokinetics of both drugs and tissue 
penetration of doxorubicin. Invest New Drugs. 2014; 
32:1269-1277. doi: 1210.1007/s10637-10014-10159-10635. 
Epub 12014 Sep 10612.
63. McStay GP, Salvesen GS and Green DR. Overlapping 
cleavage motif selectivity of caspases: implications for 
analysis of apoptotic pathways. Cell Death Differ. 2007; 
15:322-331.
Oncotarget33885www.impactjournals.com/oncotarget
64. Pereira NA and Song Z. Some commonly used caspase 
substrates and inhibitors lack the specificity required to 
monitor individual caspase activity. Biochem Biophys Res 
Commun. 2008; 377:873-877.
65. Degterev A, Hitomi J, Germscheid M, Ch’en IL, Korkina O, 
Teng X, Abbott D, Cuny GD, Yuan C, Wagner G, Hedrick 
SM, Gerber SA, Lugovskoy A and Yuan J. Identification 
of RIP1 kinase as a specific cellular target of necrostatins. 
Nat Chem Biol. 2008; 4:313-321. doi: 310.1038/
nchembio.1083.
66. Caserta TM, Smith AN, Gultice AD, Reedy MA and Brown 
TL. Q-VD-OPh, a broad spectrum caspase inhibitor with 
potent antiapoptotic properties. Apoptosis : an international 
journal on programmed cell death. 2003; 8:345-352.
67. Oberst A, Dillon CP, Weinlich R, McCormick LL, 
Fitzgerald P, Pop C, Hakem R, Salvesen GS and Green 
DR. Catalytic activity of the caspase-8-FLIP(L) complex 
inhibits RIPK3-dependent necrosis. Nature. 2011; 471:363-
367. doi: 310.1038/nature09852. Epub 02011 Mar 09852.
68. Kaiser WJ, Upton JW, Long AB, Livingston-Rosanoff 
D, Daley-Bauer LP, Hakem R, Caspary T and Mocarski 
ES. RIP3 mediates the embryonic lethality of caspase-8-
deficient mice. Nature. 2011; 471:368-372. doi: 310.1038/
nature09857. Epub 02011 Mar 09852.
69. Lin Y, Devin A, Rodriguez Y and Liu ZG. Cleavage of 
the death domain kinase RIP by caspase-8 prompts TNF-
induced apoptosis. Genes Dev. 1999; 13:2514-2526.
70. Feoktistova M, Geserick P, Kellert B, Dimitrova DP, 
Langlais C, Hupe M, Cain K, MacFarlane M, Hacker G 
and Leverkus M. cIAPs block Ripoptosome formation, a 
RIP1/caspase-8 containing intracellular cell death complex 
differentially regulated by cFLIP isoforms. Mol Cell. 2011; 
43:449-463. doi: 410.1016/j.molcel.2011.1006.1011. Epub 
2011 Jul 1017.
71. Geserick P, Hupe M, Moulin M, Wong WW, Feoktistova 
M, Kellert B, Gollnick H, Silke J and Leverkus M. Cellular 
IAPs inhibit a cryptic CD95-induced cell death by limiting 
RIP1 kinase recruitment. J Cell Biol. 2009; 187:1037-1054. 
doi: 1010.1083/jcb.200904158.
72. Lu JV, Weist BM, van Raam BJ, Marro BS, Nguyen LV, 
Srinivas P, Bell BD, Luhrs KA, Lane TE, Salvesen GS and 
Walsh CM. Complementary roles of Fas-associated death 
domain (FADD) and receptor interacting protein kinase-3 
(RIPK3) in T-cell homeostasis and antiviral immunity. 
Proc Natl Acad Sci U S A. 2011; 108:15312-15317. doi: 
15310.11073/pnas.1102779108. Epub 1102772011 Aug 
1102779129.
73. Pop C, Oberst A, Drag M, Van Raam BJ, Riedl SJ, Green 
DR and Salvesen GS. FLIP(L) induces caspase 8 activity 
in the absence of interdomain caspase 8 cleavage and alters 
substrate specificity. Biochem J. 2011; 433:447-457.
74. van Raam BJ, Ehrnhoefer DE, Hayden MR and Salvesen 
GS. Intrinsic cleavage of receptor-interacting protein 
kinase-1 by caspase-6. Cell Death Differ. 2013; 20:86-96. 
doi: 10.1038/cdd.2012.1098. Epub 2012 Aug 1033.
75. Moquin DM, McQuade T and Chan FK. CYLD 
deubiquitinates RIP1 in the TNFalpha-induced necrosome 
to facilitate kinase activation and programmed necrosis. 
PLoS One. 2013; 8:e76841. doi: 76810.71371/journal.
pone.0076841. eCollection 0072013.
76. O’Donnell MA, Perez-Jimenez E, Oberst A, Ng A, 
Massoumi R, Xavier R, Green DR and Ting AT. Caspase 
8 inhibits programmed necrosis by processing CYLD. Nat 
Cell Biol. 2011; 13:1437-1442. doi: 1410.1038/ncb2362.
77. Jeffree GM, Price CH and Sissons HA. The metastatic 
patterns of osteosarcoma. Br J Cancer. 1975; 32:87-107.
78. Gibson TM and Robison LL. Impact of Cancer Therapy-
Related Exposures on Late Mortality in Childhood Cancer 
Survivors. Chem Res Toxicol. 2015; 28:31-37.
79. Johnson GE. Mammalian cell HPRT gene mutation assay: 
test methods. Methods Mol Biol. 2012; 817:55-67.
80. Finlay D, Vamos M, Gonzalez-Lopez M, Ardecky RJ, 
Ganji SR, Yuan H, Su Y, Cooley TR, Hauser CT, Welsh 
K, Reed JC, Cosford ND and Vuori K. Small-molecule 
IAP antagonists sensitize cancer cells to TRAIL-induced 
apoptosis: roles of XIAP and cIAPs. Mol Cancer Ther. 
2014; 13:5-15. doi: 10.1158/1535-7163.MCT-1113-0153. 
Epub 2013 Nov 1155.
81. Bockbrader KM, Tan M and Sun Y. A small molecule 
Smac-mimic compound induces apoptosis and sensitizes 
TRAIL- and etoposide-induced apoptosis in breast cancer 
cells. Oncogene. 2005; 24:7381-7388.
82. Griffith TS, Kucaba TA, O’Donnell MA, Burns J, Benetatos 
C, McKinlay MA, Condon S and Chunduru S. Sensitization 
of human bladder tumor cells to TNF-related apoptosis-
inducing ligand (TRAIL)-induced apoptosis with a small 
molecule IAP antagonist. Apoptosis. 2011; 16:13-26. doi: 
10.1007/s10495-10010-10535-10493.
83. Servida F, Lecis D, Scavullo C, Drago C, Seneci P, Carlo-
Stella C, Manzoni L, Polli E, Lambertenghi Deliliers G, 
Delia D and Onida F. Novel second mitochondria-derived 
activator of caspases (Smac) mimetic compounds sensitize 
human leukemic cell lines to conventional chemotherapeutic 
drug-induced and death receptor-mediated apoptosis. Invest 
New Drugs. 2011; 29:1264-75.
84. Stadel D, Mohr A, Ref C, MacFarlane M, Zhou S, 
Humphreys R, Bachem M, Cohen G, Moller P, Zwacka 
RM, Debatin KM and Fulda S. TRAIL-induced apoptosis 
is preferentially mediated via TRAIL receptor 1 in 
pancreatic carcinoma cells and profoundly enhanced by 
XIAP inhibitors. Clin Cancer Res. 2010; 16:5734-5749. 
doi: 5710.1158/1078-0432.CCR-5710-0985. Epub 2010 
Oct 5712.
85. Abhari BA, Cristofanon S, Kappler R, von Schweinitz 
D, Humphreys R and Fulda S. RIP1 is required for IAP 
inhibitor-mediated sensitization for TRAIL-induced 
apoptosis via a RIP1/FADD/caspase-8 cell death 
Oncotarget33886www.impactjournals.com/oncotarget
complex. Oncogene. 2013; 32:3263-3273. doi: 3210.1038/
onc.2012.3337. Epub 2012 Aug 3213.
86. Schneider P, Olson D, Tardivel A, Browning B, Lugovskoy 
A, Gong D, Dobles M, Hertig S, Hofmann K, Van 
Vlijmen H, Hsu YM, Burkly LC, Tschopp J and Zheng 
TS. Identification of a new murine tumor necrosis factor 
receptor locus that contains two novel murine receptors 
for tumor necrosis factor-related apoptosis-inducing ligand 
(TRAIL). J Biol Chem. 2003; 278:5444-5454. Epub 2002 
Dec 5443.
87. Udagawa N, Takahashi N, Yasuda H, Mizuno A, Itoh K, 
Ueno Y, Shinki T, Gillespie MT, Martin TJ, Higashio K 
and Suda T. Osteoprotegerin produced by osteoblasts is an 
important regulator in osteoclast development and function. 
Endocrinology. 2000; 141:3478-3484.
88. Kushlinskii NE, Timofeev YS, Solov’ev YN, Gerstein ES, 
Lyubimova NV and Bulycheva IV. Components of the 
RANK/RANKL/OPG system, IL-6, IL-8, IL-16, MMP-2, 
and calcitonin in the sera of patients with bone tumors. Bull 
Exp Biol Med. 2014; 157:520-523. doi: 510.1007/s10517-
10014-12605-y. Epub 12014 Aug 10512.
89. Patino-Garcia A, Zalacain M, Folio C, Zandueta C, 
Sierrasesumaga L, San Julian M, Toledo G, De Las Rivas 
J and Lecanda F. Profiling of chemonaive osteosarcoma 
and paired-normal cells identifies EBF2 as a mediator of 
osteoprotegerin inhibition to tumor necrosis factor-related 
apoptosis-inducing ligand-induced apoptosis. Clin Cancer 
Res. 2009; 15:5082-5091. doi: 5010.1158/1078-0432.CCR-
5009-0300. Epub 2009 Aug 5011.
90. Neville-Webbe HL, Cross NA, Eaton CL, Nyambo R, 
Evans CA, Coleman RE and Holen I. Osteoprotegerin 
(OPG) produced by bone marrow stromal cells protects 
breast cancer cells from TRAIL-induced apoptosis. Breast 
Cancer Res Treat. 2004; 86:269-279.
91. Shipman CM and Croucher PI. Osteoprotegerin is a soluble 
decoy receptor for tumor necrosis factor-related apoptosis-
inducing ligand/Apo2 ligand and can function as a paracrine 
survival factor for human myeloma cells. Cancer Res. 2003; 
63:912-916.
92. Zhao J, Jitkaew S, Cai Z, Choksi S, Li Q, Luo J and Liu 
ZG. Mixed lineage kinase domain-like is a key receptor 
interacting protein 3 downstream component of TNF-
induced necrosis. Proc Natl Acad Sci U S A. 2012; 
109:5322-5327. doi: 5310.1073/pnas.1200012109. Epub 
1200012012 Mar 1200012115.
93. Remijsen Q, Goossens V, Grootjans S, Van den Haute C, 
Vanlangenakker N, Dondelinger Y, Roelandt R, Bruggeman 
I, Goncalves A, Bertrand MJ, Baekelandt V, Takahashi 
N, Berghe TV and Vandenabeele P. Depletion of RIPK3 
or MLKL blocks TNF-driven necroptosis and switches 
towards a delayed RIPK1 kinase-dependent apoptosis. Cell 
Death Dis. 2014; 5:e1004.(doi):10.1038/cddis.2013.1531.
94. Ho PW, Goradia A, Russell MR, Chalk AM, Milley KM, 
Baker EK, Danks JA, Slavin JL, Walia M, Crimeen-Irwin 
B, Dickins RA, Martin TJ and Walkley CR. Knockdown 
of PTHR1 in osteosarcoma cells decreases invasion 
and growth and increases tumor differentiation in vivo. 
Oncogene. 2015; 34:2922-2933.
95. Liber HL and Thilly WG. Mutation assay at the thymidine 
kinase locus in diploid human lymphoblasts. Mutation 
research. 1982; 94:467-485.
96. Uren AG, Pakusch M, Hawkins CJ, Puls KL and Vaux 
DL. Cloning and expression of apoptosis inhibitory protein 
homologs that function to inhibit apoptosis and/or bind 
tumor necrosis factor receptor-associated factors. Proc Natl 
Acad Sci USA. 1996; 93:4974-4978.
